Strategic partnerships Despite ceasing operations as of January 1, 2024, Transomic previously engaged in collaboration and licensing efforts with entities like ERS Genomics, presenting an opportunity to explore legacy license holders or collaboration partners for complementary CRISPR, RNAi, and gene expression tool kits.

Investment signals Recent investment from IMUNON indicates external interest in Transomic's technology. This suggests a potential market need for gene expression and DNA-based toolsets, presenting a lead into MSOs or portfolio companies seeking gene editing and immunotherapy support.

Academic access Historically, Transomic engaged academia (UCLA) with access to genomic tools. There may be market demand among universities and research institutes for gene expression and CRISPR/RNAi tools, opening deals through distributor resellers or academic grant channels.

Technology reach Their tech stack includes cloud, analytics, and web-based platforms. Partnering with cloud and data analytics providers or researchers requiring scalable genomic data workflows could yield opportunities for tool integration, licensing, or hosted services.

Market positioning Operating in biotech tools with peers like GenScript and Thermo Fisher, there is a potential channel strategy to target mid-market biotech and academic labs needing affordable, specialized CRISPR and gene expression resources, potentially via OEM or reseller arrangements.